Diethylcarbamazine

# Diethylcarbamazine ## Overview - **Classification**: Anthelmintic; piperazine derivative. - **Mechanism**: Immobilizes microfilariae, increasing their susceptibility to host immune system clearance. Also affects adult worms. ## Primary Indications 1. **Lymphatic Filariasis** (Wuchereria bancrofti, Brugia malayi, B. timori) - Treatment of active infection. 2. **Loiasis** (Loa loa) - Treatment of active infection. 3. **Tropical Eosinophilia (TPE)** - Treatment of Tropical Pulmonary Eosinophilia syndrome. ## Adult Dosing ### Standard Dosing **Lymphatic Filariasis** - **Dose**: **6 mg/kg/day** - **Frequency**: Divided **TID** - **Route**: Oral - **Duration**: **21 days** - **Special Consideration**: Gradual escalation often recommended to manage reactions. E.g., Day 1: **50 mg** once daily; Day 2: **50 mg** BID; Day 3: **50 mg** TID; Days 4-21: **100 mg** TID. Max **300 mg/day**. **Loiasis** - **Dose**: **9 mg/kg/day** - **Frequency**: Divided **TID** - **Route**: Oral - **Duration**: **21-28 days** - **Special Consideration**: Gradual escalation is critical to reduce risk of severe reactions. E.g., Day 1: **50 mg** once daily; Day 2: **50 mg** BID; Day 3: **50 mg** TID; Days 4-28: **100 mg** TID. Max **300 mg/day**. **Tropical Pulmonary Eosinophilia (TPE)** - **Dose**: **6 mg/kg/day** - **Frequency**: Divided **TID** - **Route**: Oral - **Duration**: **14-21 days** (often 21 days) ### Dose Adjustments - **Renal Impairment**: Reduce dose and/or extend interval. Limited specific guidance. Use with caution. - **Hepatic Impairment**: No specific guidelines. Use with caution. - **Elderly Patients**: Use with caution. Start at lower end of dosing range due to potential for decreased renal function. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Generally **not recommended**. - **Special Notes**: Limited data and high risk of severe adverse reactions. ### Infants (1-12 months) - **Dose**: Generally **not recommended**. - **Special Notes**: High risk of severe reactions (e.g., Mazzotti). Consider only if critical and no alternatives. ### Children (1-12 years) - **Dose**: **6 mg/kg/day** for Lymphatic Filariasis/TPE; **9 mg/kg/day** for Loiasis. - **Frequency**: Divided **TID** - **Maximum**: **300 mg/day** (adult maximum dose). - **Special Notes**: Gradual dose escalation is crucial, similar to adult regimens, to mitigate Mazzotti reactions. ### Adolescents (13-18 years) - **Dose**: Follow adult dosing recommendations, typically **6-9 mg/kg/day**. - **Maximum**: Adult maximum dose of **300 mg/day**. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to diethylcarbamazine. - **Absolute**: Concomitant onchocerciasis (risk of severe systemic and ocular reactions). - **Relative**: Pregnancy (Category C) – use only if clearly indicated and benefits outweigh risks. - **Relative**: Severe hypertension or history of cerebral hemorrhage/seizures (especially in Loa loa). ### Common Adverse Effects - **Very Common (>10%)**: **Mazzotti reaction** (fever, headache, myalgia, arthralgia, rash, pruritus, lymphadenopathy, edema) due to dying microfilariae. - **Common (1-10%)**: Nausea, vomiting, dizziness, weakness, anorexia. - **Serious but Rare**: Encephalopathy (especially with high Loa loa microfilarial loads), retinal hemorrhage, nephropathy. ### Key Drug Interactions - **Albendazole, Ivermectin**: Often co-administered for mass drug administration; generally safe, but monitor for additive systemic reactions. - **Drugs affecting renal function**: May alter DEC excretion; monitor renal function. ## Monitoring & Follow-up - **Before Treatment**: - Baseline assessment of filarial species and microfilarial load (especially for Loa loa). - Ocular examination if Loa loa suspected. - Baseline renal function (BUN, creatinine). - **During Treatment**: - Monitor for **Mazzotti reactions** (fever, rash, headache, joint pain) particularly during the first few days. - Monitor for clinical signs of neurological involvement (e.g., encephalopathy) in Loa loa. - **Clinical Signs**: Swelling, itching, fever, headache, joint pain (Mazzotti reaction). ## Clinical Pearls - 💡 **Tip 1**: Administer **after meals** to minimize gastrointestinal upset. - 💡 **Tip 2**: The **Mazzotti reaction** is a common and expected immune response to dying parasites; manage with supportive care, corticosteroids, and/or antihistamines. - 💡 **Tip 3**: **Always rule out onchocerciasis** before administering DEC in co-endemic areas to prevent severe adverse events. - 💡 **Tip 4**: **Gradual dose escalation** is critical, especially in Loiasis, to reduce the severity of reactions. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.